Research Analysts Issue Forecasts for BLFS Q1 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for BioLife Solutions in a report released on Monday, November 18th. HC Wainwright analyst Y. Chen expects that the medical equipment provider will post earnings of ($0.10) per share for the quarter. HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for BioLife Solutions’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.41) EPS.

BLFS has been the subject of several other reports. Craig Hallum raised their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. TD Cowen raised their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Northland Securities increased their target price on BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.50.

BioLife Solutions Trading Up 9.6 %

NASDAQ:BLFS opened at $22.44 on Wednesday. BioLife Solutions has a 52-week low of $11.91 and a 52-week high of $28.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The stock has a fifty day simple moving average of $23.92 and a 200-day simple moving average of $22.87. The company has a market capitalization of $1.04 billion, a PE ratio of -21.17 and a beta of 1.88.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in BioLife Solutions by 11.5% during the first quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock worth $53,208,000 after purchasing an additional 296,727 shares during the period. Fred Alger Management LLC grew its stake in shares of BioLife Solutions by 6.0% during the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after buying an additional 88,840 shares during the period. State Street Corp increased its holdings in shares of BioLife Solutions by 7.3% during the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after buying an additional 95,788 shares during the last quarter. Geode Capital Management LLC raised its position in shares of BioLife Solutions by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after buying an additional 18,473 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of BioLife Solutions by 9.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock worth $17,034,000 after buying an additional 66,422 shares during the period. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Aby J. Mathew sold 17,604 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $20.05, for a total transaction of $352,960.20. Following the transaction, the executive vice president now directly owns 284,442 shares in the company, valued at approximately $5,703,062.10. This represents a 5.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CRO Garrie Richardson sold 3,070 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now directly owns 114,773 shares in the company, valued at approximately $2,883,097.76. The trade was a 2.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 69,644 shares of company stock worth $1,527,503. 2.20% of the stock is owned by insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.